Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Health Care Sector · Voya

Nomura Healthcare Fund Class A (DLHAX)

Ticker DLHAX · · Holdings as of Jun 30, 2026

Expense ratio
1.21%$121/yr per $10k
5-yr return
+6.2%annualized
1-yr return
+15.1%as of Dec 2025
Net assets
$750.2Mall share classes
Holdings
108

Bottom line

Is DLHAX a good fund? The bottom line

DLHAX is the Class A share class of Nomura Healthcare Fund, an actively managed health care sector mutual fund from Voya.

It charges 1.21% — about $121 a year on every $10,000 invested, more expensive than 70% of health care sector funds we track.

It returned +15.1% over one year, +6.2% a year over five years, +9.5% a year over ten (as of Dec 31, 2025, per its prospectus).

With $750 million in net assets and 108 holdings, its largest position is Ucb Sa (5.2%) and the top 10 make up 38.9% of the portfolio.

This share class carries a front-end sales charge of up to 5.75%; a no-load class or ETF alternative can avoid it.

What stands out

  • 5-year return beat 73% of category peers

What to watch

  • Front-end sales load up to 5.75%
  • 12b-1 marketing fee of 0.25% a year

Updated Nov 19, 2026

What DLHAX invests in

Nomura Healthcare Fund seeks maximum long-term capital growth through capital appreciation.

Under normal circumstances, Nomura Healthcare Fund ?will invest at least 80% of its net assets, plus the amount of any borrowings for investment purposes, in the equity securities of healthcare companies (80% policy). For purposes of the Funds 80% policy, healthcare companies include those companies that develop, produce, or distribute products or services related to the healthcare or medical industries and derive a substantial portion of their sales from products and services in the healthcare industry. These products and services include, but are not limited to, pharmaceutical companies, biotechnology companies, medical device and supply companies, managed care companies, and healthcare information and service providers. The Fund invests in US and non-US companies across all market capitalizations. The Fund may invest up to 50% of its total assets in non-US companies. The Fund may…

From the fund's prospectus (filed Jul 29, 2026).

DLHAX performance

Fund calendar-year total returns, 2015–2025 2015: +11.4%; 2016: −4.3%; 2017: +32.0%; 2018: −0.8%; 2019: +31.5%; 2020: +11.1%; 2021: −5.3%; 2022: −1.3%; 2023: +4.2%; 2024: +8.5%; 2025: +22.1% +11% 2015 −4% 2016 +32% 2017 −1% 2018 +32% 2019 +11% 2020 −5% 2021 −1% 2022 +4% 2023 +8% 2024 +22% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
DLHAX+15.1%+6.2%+9.5%
Health Care Sector median+14.5%+4.2%+7.9%

Source: Fund prospectus, as of Dec 31, 2025

Full DLHAX performance history →

What DLHAX costs

On a $10,000 investment, DLHAX's 1.21% expense ratio costs about $121 a year. The prospectus estimates $2,006 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.

See the full DLHAX fee table →

DLHAX top 10 holdings

#Holding% of fund
1Ucb Sa UCB5.19%
2Abbvie Inc ABBV4.19%
3Eli Lilly & Company LLY4.16%
4Regeneron Pharmaceuticals Inc REGN3.91%
5Unitedhealth Group Inc UNH3.88%
6Pfizer Inc PFE3.84%
7Merck & Company Inc MRK3.68%
8Gilead Sciences Inc GILD3.54%
9Astrazeneca Plc AZN3.27%
10Elevance Health Inc ELV3.25%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 38.9% of the fund. See all top 25 holdings and asset mix →

Alternatives to DLHAX

More funds like DLHAX →

DLHAX FAQ

What is the expense ratio of DLHAX?
DLHAX's expense ratio is 1.21%, which works out to about $121 a year for every $10,000 invested. The prospectus estimates total costs of $2,006 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is DLHAX a good investment?
It depends on your goals, but the data points to: 5-year return beat 73% of category peers; front-end sales load up to 5.75%; 12b-1 marketing fee of 0.25% a year. This is general information, not personalized advice.
What does DLHAX hold?
DLHAX's largest holdings are Ucb Sa (5.2%), Abbvie Inc (4.2%), Eli Lilly & Company (4.2%), Regeneron Pharmaceuticals Inc (3.9%), Unitedhealth Group Inc (3.9%). It holds 108 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is DLHAX's 5-year return?
DLHAX returned +6.2% a year over the five years ending Dec 31, 2025, and +9.5% a year over ten years. Past performance does not guarantee future results.
Does DLHAX have a sales load?
Yes. DLHAX has a maximum front-end sales charge of 5.75%.
Who manages DLHAX?
DLHAX is offered by Voya through Delaware Group Equity Funds IV.